Financial News

Geron to Present at the J.P. Morgan Healthcare Conference

Geron Corporation (Nasdaq:GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company’s product development programs at 3:30 p.m. PST on Wednesday, January 13, 2010, at the J.P. Morgan 28th Annual Healthcare Conference in San Francisco.

The presentation will include updates on Geron’s telomerase inhibitor drug (imetelstat sodium - GRN163L) and telomerase therapeutic vaccine (GRNVAC1) as well as the company’s human embryonic stem cell development programs for spinal cord injury (GRNOPC1), heart disease (GRNCM1), diabetes (GRNIC1), and osteoarthritis (GRNCHND1).

The webcast link for the live audio and slide presentation will be available on the Events page in the Investors section of Geron’s website at http://www.geron.com/investors/factsheet/events.aspx. The presentation will be archived for replay shortly after the live event and available for 30 days.

About Geron

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials in different cancers. For more information, visit www.geron.com.

Contacts:

Geron Corporation
Anna Krassowska, Ph.D., 650-473-7765
Investor and Media Relations
info@geron.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback